Shares of Aptose Biosciences Inc. (NASDAQ:APTO) rose 5.8% on Friday . The stock traded as high as $2.20 and last traded at $2.20, with a volume of 52,729 shares trading hands. The stock had previously closed at $2.08.

APTO has been the subject of several research analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a research note on Thursday, June 9th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $23.00 price target on shares of Aptose Biosciences in a research note on Saturday, June 25th. Roth Capital raised shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $4.00 to $8.00 in a research note on Monday, June 13th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, June 9th. Finally, Zacks Investment Research downgraded shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $12.30.

The firm’s market capitalization is $28.36 million. The company has a 50-day moving average price of $2.40 and a 200 day moving average price of $2.59.

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.